Evidence map›Paper›PMID 39934623›Full record

Trial reportDigestive diseases and sciences2025

Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication with Radiofrequency Ablation.

Robert S Bresalier, Nicholas J Shaheen, Mike Hernandez, Navtej Buttar, Norman Marcon, Sachin Wani, Raman Muthusamy, Gary Falk, Tamara Tipps Johnson, Peiying Yan and 7 more

Abstract readRandomized Controlled TrialClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Robert S BresalierDepartment of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. rbresali@mdanderson.org.
Nicholas J ShaheenCenter for Esophageal Diseases and Swallowing, The University of North Carolina, Chapel Hill, NC, USA.
Mike HernandezDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard Unit 1466, Houston, TX, 77030, USA.
Navtej ButtarDepartment of Gastroenterology, Mayo Clinic, Rochester, MN, USA.
Norman MarconDepartment of Gastroenterology, St. Michael's Hospital, Toronto, Canada.
Sachin WaniDepartment of Gastroenterology, University of Colorado, Aurora, CO, USA.
Raman MuthusamyDepartment of Gastroenterology, University of California, Los Angeles, CA, USA.
Gary FalkDepartment of Gastroenterology, University of Pennsylvania, Philadelphia, PA, USA.
Tamara Tipps JohnsonDepartment of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Peiying YanDepartment of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xiaofang HuoUniversity of Texas Southwestern Medical Center, Dallas, TX, USA.
Tawana A CastilleDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Gary Della'ZannaDivision of Cancer Prevention, National Cancer Institute, Rockville, Maryland, USA.
Ellen RichmondDivision of Cancer Prevention, National Cancer Institute, Rockville, Maryland, USA.
J Jack LeeDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard Unit 1466, Houston, TX, 77030, USA.
Powel BrownDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rhonda SouzaCenter for Esophageal Research, Baylor Scott & White Research Institute, Dallas, TX, USA.

Funding

NCI NIH HHS NO1 CN-2012-00034 Contract HHSN2612012000341
6 · The paper itself

Abstract

OBJECTIVES/

methodsPlacebo-controlled phase II study evaluated aspirin's effect on CDX2 mRNA and prostanoid production in native and neosquamous epithelium after successful radiofrequency ablation (RFA) in Barrett's esophagus.

resultsAt 12 months TXB2, PGF2α, PGD2, PGE2, PGE1, and α13PGE2 increased in native squamous but not neosquamous epithelium in individuals randomized to placebo. Aspirin use significantly reduced CDX2 mRNA in native squamous epithelium, and was associated with decreases in PGE1, PGE2 and 13PGE2 in neosquamous epithelium.

conclusionsAfter RFA, native squamous and neosquamous epithelium exhibit different molecular markers and responses to aspirin suggesting that different sources of squamous progenitors contribute to esophageal re-epithelization.

Indexed as

AspirinBarrett EsophagusRadiofrequency AblationAgedBiomarkersCDX2 Transcription FactorDouble-Blind MethodFemaleHumansMaleMiddle AgedRNA, MessengerTreatment OutcomeAspirinBiomarkersCDX2 protein, humanCDX2 Transcription FactorRNA, MessengerBarrett’s esophagusCDX2ChemopreventionEicosanoidsRadiofrequency ablation

Identifiers

PMID39934623

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.